-
Mashup Score: 8Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 2 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 8Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 7Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 7Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 7Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 6Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - 3 month(s) ago
Summary:. Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd
-
-
Mashup Score: 5
Abstract. T-cell exhaustion poses a significant barrier to the efficacy of immunotherapies. In the past decade, immune checkpoint blockade (ICB) has been the leading strategy to prevent or reverse T-cell exhaustion. Although ICB yields promising clinical outcomes in patients with cancer, its impact on T-cell reinvigoration is often short-lived. High-throughput genomic tools, including CRISPR screening along with single-cell RNA and chromatin accessibility sequencing may point toward new therapeutic avenues. However, their utility in identifying key mediators of T-cell exhaustion is constrained by the restricted scalability of well-validated in vivo exhaustion models, like chronic LCMV infection. In a recent article in Science Immunology, Wu and colleagues introduce an in vitro exhaustion model that involves repetitive stimulation of T-cell receptor-transgenic, LCMV-specific P14 CD8 T cells. This approach enables a direct comparison of exhausted T (Tex) cells generated both in vivo and
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
Read the In the Spotlight commentary in this issue— Unraveling #Tcell exhaustion: genetic screening meets in vitro modeling, by @AlfredZippelius, @MarcelTrefny, @priska_adm, and Schmid describing a recent @SciImmunology paper from the @EJohnWherry group. https://t.co/JxVCqGCExu https://t.co/fpq6QSKewf
-
-
Mashup Score: 8Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment - 5 month(s) ago
Patients with head and neck squamous cell carcinoma that responded to dual PD-1/CTLA4 immune checkpoint blockade exhibited a parallel remodeling of the activated CD4+ regulatory T-cell (Treg) and dysfunctional CD8+ T-cell compartments.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
From the most recent issue Cancer Discovery— Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ #Tcell and Activated Treg Compartment, by Anne van der Leun, Joleen Traets, @Schumacher_lab, Charlotte Zuur et al. https://t.co/FZYOVCCdvK @NKI_nl https://t.co/FpmMdSXRdY
-
-
Mashup Score: 1Formate supplementation enhances anti-tumor CD8+ T cell fitness and efficacy of PD-1 blockade - 6 month(s) ago
Abstract. The tumor microenvironment (TME) restricts anti-tumor CD8+ T cell function and immunotherapy responses. Cancer cells compromise metabolic fitness of CD8+ T cells within the TME, but the mechanisms are largely unknown. Here we demonstrate one carbon (1C) metabolism is enhanced in T cells in an antigen-specific manner. Therapeutic supplementation of 1C metabolism using formate enhances CD8+ T cell fitness and anti-tumor efficacy of PD-1 blockade in B16-OVA tumors. Formate supplementation drives transcriptional alterations in CD8+ T cell metabolism and increases gene signatures for cellular proliferation and activation. Combined formate and anti-PD-1 therapy increases tumor-infiltrating CD8+ T cells, which are essential for the enhanced tumor control. Our data demonstrate formate provides metabolic support to CD8+ T cells reinvigorated by anti-PD-1 to overcome a metabolic vulnerability in 1C metabolism in the TME to further improve T cell function.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In Focus— Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. https://t.co/GlqH5dy9Yr https://t.co/F7tHo1PPJd